SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ron Schipper who wrote (244)5/10/1997 8:05:00 PM
From: harkenman   of 998
 
I believe that insults are uncalled for since we share our opinions, beliefs, knowledge and hopes on this thread.

I think that ONXX approach to treatment using the p53 gene is a novel way of treating a disease. RPR is also working on a similar approach. I believe that the future in treatment of unmet medical needs will be addressed using biotechnological approaches. The conventional structure activity relationship (SAR) approach is coming to an end. Companies like ELN, ZEN, GLX, MRK, CYTO, are seeking new approaches such as gene mapping to develop drug therapies.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News